Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
US measles cases surpass 2,000, highest in 30 years: CDC - 2Conquering Social Generalizations: Individual Accounts of Strengthening
- 3Scientists are getting our robotic explorers ready to help send humans to Mars
- 4Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- 5Ancient fire discovery marks significant milestone in human history
- Exploring the School Application Cycle: Understudy Bits of knowledge
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- How to watch 'Tell Me Lies' Season 3: Episode release times, streaming info and more
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- Tech for Wellbeing: Applications and Devices for a Better You
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says
- A Manual for Extravagant Vehicles Available in 2024
- Bayer sues COVID vaccine makers over mRNA technology
